Update in the management of head and neck cancer

Update on Cancer Therapeutics

Volumn 1, Issue 2, 2006, Pages 211-219

  Fanucchi, Michael ^a   Khuri, Fadlo R ^a   Shin, Dong ^a   Johnstone, Peter A S ^a   Chen, Amy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Head and neck cancer; Otolaryngology; Radiation; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; LARYNGECTOMY; LARYNX; LARYNX CARCINOMA; LASER SURGERY; LOW LEVEL LASER THERAPY; METASTASIS; MUCOSA INFLAMMATION; NONHUMAN; ORGAN PRESERVATION; PATIENT CARE; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RASH; REVIEW; SALIVARY GLAND DISEASE; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURGEON; WEIGHT REDUCTION;

EID: 33746308416     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.04.006     Document Type: Review

References (42)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics. CA Cancer J Clin 54 (2004) 8-29
2. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 19 (2004) 1945-1951
3. Cooper J., Pajak T.F., Forastiere A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 19 (2004) 1937-1944
4. Fu K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
5. Forastiere A., Koch W., Trotti A., et al. Head and neck caner. N Engl J Med 345 26 (2001) 1890-1900
6. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 22 1 (2004) 69-76
7. Adelstein D., Li Y., Adams G., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 1 (2003) 92-98
8. Zorat P.L., Loreggian L., Paccagnella A., et al. Randomized phase III trial of neoadjuvant chemotherapy (CT) in head and neck (H&N) cancer patients: an update based on 10 years' follow up. Proc Am Soc Clin Oncol 22 14S (2004) 14s
9. Vermorken J.B., Remenar E., Van Herpen C., et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Proc Am Soc Clin Oncol 22 (2004) 14s
10. Hitt R., Lopez-Pousa A., Rodriguez M., et al. Phase III study comparing cisplatin (P) and 5-fluoruracil (F) versus P, F, and paclitaxel (T) as induction therapy in locally advanced head and neck cancer (LAHNC). Proc Am Soc Clin Oncol 22 (2003) 496
11. Bonner J.A., Harari P.M., Girait J., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 22 14S (2004)
12. Forastiere A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 22 (2003) 2091-2098
13. Jacobs C., Lyman G., Velez-Garcia E., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10 (1992) 257-263
14. Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 10 (1992) 1245-1251
15. Forastiere A., Leong T., Rowinsky E., et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Co-operative Oncology Group Study E1393. J Clin Oncol 19 (2001) 1088-1095
16. Murphy B., Li Y., Cella D., et al. Phase III study comparing cisplatin and 5-flurouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 20 (2001) 224a
17. Wells N., Murphy B., Dietrich M., et al. Quality of life and pain assessment for head and neck cancer patients treated on E1395: a comparison of two different cisplatin-based chemotherapy regimens. Proc Am Soc Clin Oncol 21 (2002) 228A
18. Argiris A., Li Y., and Forastiere A. Prognostic factors and long term survivorship in patients with recurrent or metastatic head and neck cancer (HNC): an analysis of two Eastern Cooperative Oncology Group (ECOG) randomized trials. Proc Am Soc Clin Oncol 22 (2004) 14s
19. Glisson B., Murphy B., Frenette G., et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20 (2002) 1593-1599
20. Specht L., Larsen S., and Hansen H. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 11 (2000) 845-849
21. Schoffski P., Catimel G., Planting A.S., et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10 (1999) 119-122
22. Fountzilas G., Skarlos D., Athanassiades A., et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 8 (1997) 451-455
23. Pivot X., Cals L., Cupissol D., et al. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology 60 (2001) 66-71
24. Shin D.M., Glisson B., Khuri F.R., et al. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 25 (1998) 40-48
25. Shin D.M., Khuri F., Glisson B.S., et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91 (2001) 1316-1323
26. Janinis J., Papadakou M., Xidakis E., et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer. Am J Clin Oncol 23 (2000) 128-131
27. Cohen E., Rosen F., Dekker A., et al. Phase II trial of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
28. Soulieres D., Senzer N., Vokes E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 1 (2004) 77-85
29. Shin D.M., Donato N., Cooper M., et al. Epidermal growth factor receptor targeted therapy with humanized chimeric monoclonal antibody, C225, in combination with cisplatin in patients with head and neck cancer. Clin Cancer Res 7 (2001) 1204-1213
30. Baselga J., Trigo J., Bourhis J., et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 21 (2002) 226A
31. Kies M., Arquette M., Nabell L., et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Eribitux (IMC-225) in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 21 (2002) 232A
32. Trigo J., Hitt R., Koralewski P., et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. Proc Am Soc Clin Oncol 22 (2004) 14s
33. Burtness B., Li Y., Flood W., et al. Phase III trial comparing cisplatin + placebo to cisplatin + anti-epidermal growth factor anitbody C225 in patients with metastatic/recurrent head and neck cancer. Proc Am Soc Clin Oncol 21 (2002) 226A
34. Johnson J.T., Ferretti G.A., Nethery W.J., Vadez I.H., Fox P.C., Ng D., et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. J Am Med Assoc 329 (1993) 390-395
35. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
36. Esiashvili N., Koshy M., and Landry J.C. Intensity modulated radiation therapy. Curr Probl Cancer 28 (2004) 43-84
37. Koshy M., Pauline A.C., Howell R., Schuster D., Halkar R., and Davis L.W. F18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 27 (2005) 494-502
38. Steiner W., Ambrosch P., Hess C.F., and Kron M. Organ preservation by transoral laser microsurgery in pyriform sinus carcinoma. Oto-Head Neck Surgery 125 1 (2001) 58-67
39. Iro H., Waldfaherer F., Altendorf, Hofmann A., Weidenbecher M., Sauer R., et al. Transoral laser surgery of supraglottic cancer: follow-up of 141 patients. Archive Oto-HNS 124 11 (1998) 1245-1250
40. Weber R.S., Forastiere A., Rosenthal D.I., and Laccourreye O. Controversies in the management of advanced laryngeal squamous cell carcinoma. Cancer 101 2 (2004) 211-219
41. Laccourreye O., Ishoo E., Mones E.D., Garcia D., Kania R., and Hans S. Supracricoid hemilaryngopharyngecomy in patients with invasive squamous cell carcinoma of the pyriform sinus. Ann Otol Rhinol Laryngol 114 (2005) 25-34
42. Ross G.L., Soutar D.S., Macdonald G.D., et al. Sentinel lymph node biopsy in head and neck cancer: preliminary results of a multicenter trial. Ann Surg Oncol 11 7 (2004) 690-696